Unknown

Dataset Information

0

Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions.


ABSTRACT:

Background

Co-trimoxazole has been reported as a common culprit drug for various cutaneous adverse drug reactions (CADRs). However, information on genotypic and phenotypic characteristics is still limited. We aimed to study clinical characteristics, genetic suitability, laboratory findings, and treatment outcomes in patients with co-trimoxazole-induced CADR and determine variables associated with severe cutaneous adverse reactions (SCARs).

Methods

The medical records of all patients diagnosed with co-trimoxazole-induced CADR during October 2015 and October 2021 were reviewed. Clinical characteristics and laboratory investigation with an emphasis on human leukocyte antigen (HLA) class I and HLA-DRB1 results linked to subtypes of cutaneous adverse reactions were evaluated.

Results

Seventy-two patients diagnosed with co-trimoxazole-induced CADR were included in the study. Mean age at diagnosis was 38.0 ± 14.6 years old, and 72% were female. Subtypes of reactions included maculopapular eruption (MPE; 56.9%), drug reaction with eosinophilia and systemic symptoms (DRESS; 23.6%), Stevens-Johnson syndrome (SJS; 12.5%), fixed drug eruption (4.2%), and urticaria (2.8%). Characteristics that were significantly associated with SCARs included male gender (OR = 3.01, 95% CI: 1.04-8.75), HIV infection (OR = 3.48, 95% CI: 1.13-10.75), prophylactic use of co-trimoxazole (OR = 4.89, 95% CI: 1.54-15.57), and co-trimoxazole administration longer than 10 days (OR = 7.65, 95% CI: 2.57-22.78). HLA-B*38:02 was associated with co-trimoxazole-induced SJS, while HLA-A*11:01, HLA-B*13:01, and HLA-DRB1*12:01 were associated with co-trimoxazole-induced DRESS. HLA-B*52:01 was associated with co-trimoxazole-induced MPE.

Conclusions

Co-trimoxazole could induce various phenotypes of CADRs. Genotypic and phenotypic factors that may potentially predict co-trimoxazole-induced SCARs include male gender, HIV infection, prophylactic and prolonged drug use, as well as the presence of HLA-A*11:01, HLA-B*13:01, HLA-B*38:02, or HLA-DRB1*12:01 alleles.

SUBMITTER: Iamsumang W 

PROVIDER: S-EPMC10711762 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions.

Iamsumang Wimolsiri W   Chanprapaph Kumutnart K   Sukasem Chonlaphat C   Satapornpong Patompong P   Thadanipon Kunlawat K   Suchonwanit Poonkiat P   Jantararoungtong Thawinee T   Anuntrangsee Tanaporn T  

Dermatology (Basel, Switzerland) 20231004 6


<h4>Background</h4>Co-trimoxazole has been reported as a common culprit drug for various cutaneous adverse drug reactions (CADRs). However, information on genotypic and phenotypic characteristics is still limited. We aimed to study clinical characteristics, genetic suitability, laboratory findings, and treatment outcomes in patients with co-trimoxazole-induced CADR and determine variables associated with severe cutaneous adverse reactions (SCARs).<h4>Methods</h4>The medical records of all patien  ...[more]

Similar Datasets

| S-EPMC6039997 | biostudies-other
| S-EPMC4013087 | biostudies-literature
| S-EPMC8717071 | biostudies-literature
| S-EPMC11291224 | biostudies-literature
| S-EPMC7485959 | biostudies-literature
| S-EPMC9372413 | biostudies-literature
| S-EPMC5467955 | biostudies-literature
| S-EPMC5351112 | biostudies-literature
| S-EPMC4529157 | biostudies-literature
| S-EPMC6505804 | biostudies-literature